Drug
Vortioxetine 10
Vortioxetine 10: highest development phase Phase 3, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Vortioxetine 10-20 mg NCT02279953 | Phase 3 | Major Depressive Disorder |
Latest
No recent events.
Follow Vortioxetine 10 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.